Library
Conditions, interactions, comparisons. Each guide covers history, pharmacology, dosage ranges, risks, legal status, and integration. Research-cited and reviewed by a clinical researcher.
Substances
Conditions
Per-diagnosis guides: pharmacology, evidence tier, community signal, interactions, integration. Browse the full conditions hub.
LSD and Chronic Lyme Disease: Community Signal, Mechanism, and Safety
Chronic Lyme disease and post-treatment Lyme syndrome (PTLDS) affect a substantial fraction of treated Lyme patients. Standard care after the antibiotic course is limited.
Microdosing & Psychedelics for Endometriosis: Mechanism, Evidence, and What People Report
What research suggests about psilocybin microdosing for endometriosis pain, where the evidence stops, and how to navigate drug interactions with hormonal treatments and pain
Microdosing & Psychedelics for Multiple Sclerosis: Mechanism, Evidence, and What People Report
What research suggests about psilocybin for MS symptom management, where the evidence stands, critical drug interactions with disease-modifying therapies, and how the MS community
Microdosing for Anxiety: the Edge of the Evidence
What survey data, the Maastricht placebo-controlled trial, and a decade of clinical experience say about psilocybin and LSD microdosing for anxiety. Where it helps,
Microdosing for Depression: Where the Survey Data Diverges From the Trials
Microdosing depression survey data is consistently positive. Placebo-controlled trials are not. The full-dose protocols win where microdosing fails. Here is how to think about
Microdosing for Fibromyalgia: Central Sensitization, Chronic Pain, and the Open Pilot Data
Fibromyalgia sits at the intersection of chronic pain, sleep dysfunction, and emotional dysregulation. Standard care helps modestly. Phase 2 psilocybin trials are running at
Microdosing for Menstrual Pain (Dysmenorrhea): Mechanism, Evidence, and What People Report
What the chronic-pain literature suggests about psilocybin and LSD microdosing for severe period cramps, where the evidence stops, and how to navigate NSAIDs, hormonal
Microdosing for Migraines: The Schindler Yale Trial and What It Suggests
Yale's Schindler group built the modern psilocybin headache program. Their Phase 2 migraine pilot showed reduced attack frequency from a single low dose. The
Microdosing for PMS and PMDD: Psilocybin, LSD, and What People Report
What the mood and serotonergic literature suggests about psilocybin and LSD microdosing for premenstrual dysphoria, where the evidence stops, and how to navigate SSRIs,
Microdosing for Ulcerative Colitis & Crohn's Colitis
What the research actually supports about psilocybin microdosing as an adjunct to standard IBD care, where the evidence ends, and what hard contraindications you
Psilocybin for Cluster Headaches: The Cluster-Busters Story
The condition has been called "suicide headaches" for a reason. Sub-hallucinogenic doses of psilocybin and LSD have a stronger off-label community track record here
Psilocybin for Eating Disorders: Anorexia, Bulimia, BED
Why a condition rooted in self-image distortion and rigid identity may respond to a treatment that loosens both. The Peck-Spaeth anorexia trial, the JHU
Microdosing pages
Microdosing for ADHD: Focus, Hyperactivity, Executive Function
What the research actually shows about psilocybin and LSD microdosing for adult ADHD, where it works in the survey data, where it disappoints in
Microdosing for SIBO & Gut-Brain Axis Symptoms
SIBO comes back in nearly half of patients within 9 months of standard antibiotic treatment. The gut-brain axis offers a different angle. What the
Microdosing LSD
LSD microdosing protocols. Longer active window than psilocybin, lower volume threshold. Sub-perceptual dosing applied to focus, mood, and creativity.
Psilocybin pages
Psilocybin for OCD: The Moreno 2006 Pilot, the Yale Trial, and the 5-HT2A Logic
OCD is one of the few conditions with a published psilocybin pilot study (Moreno 2006). Yale is now running a Phase 2 protocol. The
Psilocybin for PTSD: Trauma, Memory Reconsolidation, Trial Evidence
What MAPS Phase 2/3 data, the Imperial and JHU psilocybin trials, and a decade of trauma research actually show. Plus the protocols, the screening,
Psilocybin for Smoking Cessation: The Johns Hopkins 80% Number, in Context
The Hopkins pilot study showed 80% biologically verified abstinence at 6 months. That number is real, and it deserves both the excitement and the
Psilocybin for Treatment-Resistant Depression
The COMPASS Phase 3 trial, the Goodwin NEJM data, what 25 mg actually does at six months, and how this compares to ketamine and
Drug interactions (harm reduction)
ADHD Stimulants and Psilocybin: Cardiovascular Load and Anxiety Stacking
Adderall, Vyvanse, Ritalin, and Concerta are some of the most commonly prescribed psychiatric medications. Their interaction with psilocybin is not life-threatening in healthy adults
Alcohol and Psilocybin: Why It Blunts the Trip and Stacks the Risks
Alcohol and psilocybin is the most common combination people ask about because both are widely used. Pharmacologically the picture is unflattering: alcohol blunts the
Anti-Epileptics and Psilocybin: A Per-Drug Answer for AED Interactions
Anti-epileptic drugs (AEDs) are not a single class with a shared mechanism. Valproate is a broad GABA and sodium-channel modulator that also inhibits UGT
Antihistamines and Psilocybin
Antihistamines split sharply into two groups. First-generation (diphenhydramine / Benadryl, doxylamine / Unisom, hydroxyzine, promethazine) are sedating and strongly anticholinergic. Combining them with psilocybin
Antipsychotics and Psilocybin: Receptor Block, Diagnosis Caution
Most atypical antipsychotics (olanzapine, quetiapine, risperidone, aripiprazole) are 5-HT2A antagonists. That is the same receptor psilocin activates. The result is predictable: they blunt or
Benzodiazepines and Psilocybin: Trip Killer, Rescue Tool, and the Daily-Use Trap
Benzodiazepines (Xanax, Klonopin, Ativan, Valium) are the most reliable way to shorten or abort a difficult psilocybin experience, which is exactly why therapists keep
Beta-Blockers and Psilocybin: Likely Safe, Sometimes Useful for the Cardiovascular Rise
Beta-blockers (propranolol, metoprolol, atenolol, bisoprolol, carvedilol, nebivolol) block β1 and β2 adrenergic receptors. They reduce heart rate and blood pressure. They do not touch
Birth Control and Psilocybin: No Pharmacological Interaction, with Practical Notes
Hormonal contraceptives (combined oral pills, progestin-only pills, hormonal IUDs, implants, vaginal rings, patches, depot injections) act on estrogen and progesterone receptor pathways. They do
Bupropion and Psilocybin: The Non-Serotonergic Antidepressant That Still Wants a Pause
Bupropion (Wellbutrin, Zyban) is the antidepressant people most often hope is safe to combine with psilocybin, because it is not serotonergic. The good news
Cannabis and Psilocybin: Common, Not Catastrophic, Sometimes Counterproductive
The most asked combination in microdosing forums after SSRIs. The interaction is not life-threatening but can amplify anxiety, intensify the trip, and undermine integration.
DXM and Psilocybin: Serotonin Syndrome Risk From an Over-the-Counter Cough Medicine
Dextromethorphan is the cough suppressant in Robitussin, Delsym, NyQuil, and dozens of OTC combination products. It is also a serotonin reuptake inhibitor and an
Gabapentinoids and Psilocybin: No Serotonin Pathway, Sedation and Blunting Concerns, Hard Rules Against Abrupt Stopping
Gabapentin and pregabalin (Lyrica) bind the α2δ subunit of voltage-gated calcium channels. They do not touch serotonin, MAO, or 5-HT2A. The pharmacological interaction with
Ketamine and Psilocybin: Different Receptor Systems, Real Cardiovascular and Psychological Stacking
Ketamine is an NMDA antagonist and a dissociative. Psilocybin is a 5-HT2A agonist and a classical psychedelic. There is no shared serotonergic pathway, so
Lamotrigine and Psilocybin: A Mood Stabilizer That Quiets the Glutamate Echo
Lamotrigine (Lamictal) is a sodium-channel blocker that suppresses glutamate release. Psilocybin produces much of its cortical signal through 5-HT2A activation that triggers a downstream
Lithium and Psilocybin: The Most Documented Dangerous Combination
Of all psychedelic drug interactions, this one has the largest case series and the most consistent signal. Seizures, prolonged psychotic reactions, hospitalizations. The combination
MAOIs and LSD: Real Serotonin Syndrome Risk
MAOIs flood the brain with serotonin. LSD activates the receptors that flood is hitting. The combination has well-documented case reports of severe serotonin syndrome,
MDMA and Psilocybin: Hippie Flipping and the Real Risks
"Hippie flipping" is a real combination with a long recreational history. Pharmacologically the picture is more complicated than either alone: serotonin demand spikes, neurotoxicity
NSAIDs and Psilocybin: Likely Safe with GI and Hydration Notes
NSAIDs (ibuprofen, naproxen, aspirin, diclofenac, celecoxib) inhibit cyclooxygenase. They do not touch serotonin receptors and do not interact pharmacologically with psilocybin in any meaningful
Opioids and Psilocybin: Lower Acute Risk Than Tramadol, Real Practical Problems
Pure mu-opioid agonists like oxycodone, hydrocodone, morphine, and fentanyl do not share tramadol's serotonergic mechanism. Acute pharmacology is largely additive sedation, not serotonin syndrome.
PPIs and Psilocybin
Proton pump inhibitors (omeprazole, esomeprazole, pantoprazole, lansoprazole, rabeprazole, dexlansoprazole) suppress gastric acid by blocking the H+/K+ ATPase in stomach parietal cells. They do not
Psilocybin Plus MDMA Plus Amphetamine Stack: The Three-Way Combination Risk Profile
The two-substance combination of psilocybin and MDMA, sometimes called hippie flipping, has a substantial recreational history and modest documented harm profile when both substances
SSRIs and Psilocybin: Why Serotonin Syndrome Theory Diverges From Clinical Reality
The textbook warning is serotonin syndrome. The clinical data tells a different story: most SSRIs blunt the psilocybin experience rather than amplify it. Here
Statins and Psilocybin: A Cholesterol Drug Talking to a Liver Pathway That Does Not Matter for Psilocin
Statins (atorvastatin, rosuvastatin, simvastatin, pravastatin, pitavastatin, lovastatin, fluvastatin) lower LDL by blocking HMG-CoA reductase, the rate-limiting enzyme of hepatic cholesterol synthesis. They do not
Thyroid Medication and Psilocybin: Replacing a Hormone Does Not Touch the Serotonin System, with a Note on Untreated Hyperthyroidism
Levothyroxine (Synthroid, Eltroxin, Euthyrox, Tirosint) and liothyronine (Cytomel) are hormone replacements for an underactive thyroid. They restore physiological levels of T4 and T3 and
Tramadol and Psilocybin: Underestimated Serotonin Syndrome Risk
Tramadol looks like a benign opioid analgesic. It is also a serotonin reuptake inhibitor with a meaningful seizure-threshold effect. Combined with psilocybin, the case
Trazodone and Psilocybin: The Sleep Aid That Camps on the Receptor You Need
Trazodone is a SARI (serotonin antagonist and reuptake inhibitor) with high affinity for 5-HT2A as an antagonist. That is the same receptor psilocin needs
Compare
Amanita Muscaria vs Psilocybin: They Are Not the Same Mushroom
Both are "magic mushrooms" in casual use. Pharmacologically they could not be more different. Psilocybin acts on serotonin. Amanita acts on GABA and glutamate
Microdose vs Macrodose for Depression: Different Logic, Different Evidence
The same molecule at two scales does very different things. Microdose plays a long, subtle game grounded in survey data. Macrodose plays a single
Psilocybin vs Ketamine for Depression: Different Drugs, Different Tools
Both have rapid antidepressant effects. They work through different receptor systems, have different access realities, and fit different clinical pictures. For treatment-resistant depression the
Psilocybin vs LSD: Same Receptor, Different Tool
Both are 5-HT2A agonists. Both produce the classical psychedelic experience. The differences (duration, dose precision, headspace, microdosing fit) are practical rather than mechanistic. Here
